Evolocumab(anti-PCSK9), 9 型枯草蛋白酶/kexin 抗体

COA

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 小鼠(Mouse), 食蟹猴(Cynomolgus monkey)
亚型: Human IgG2
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab169287-100μg	100μg	现货
Ab169287-1mg	1mg	现货
Ab169287-5mg	5mg	现货
Ab169287-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: PCSK9

Accession#:Q8NBP7 (14) Amino Acid/Protein Metabolism (4559) Gene ID:255738 (14) PCSK9 (14) proprotein convertase subtilisin/kexin type 9 Antibody (6)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Evolocumab(anti-PCSK9), 9 型枯草蛋白酶/kexin 抗体
别名	依洛尤单抗 \| 依洛尤单抗(抗 PCSK9)
英文别名	Convertase subtilisin/kexin type 9 preproprotein antibody \| FH3 antibody \| HCHOLA3 antibody \| Hypercholesterolemia autosomal dominant 3 antibody \| LDLCQ1 antibody \| NARC 1 antibody \| NARC-1 antibody \| NARC1 antibody \| Neural apoptosis regulated convertase
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	PCSK9
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	9 型枯草蛋白酶/kexin 抗体

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG2
轻链亚型	lambda
SDS-PAGE	28.7 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 175.8 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-AC, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1256937-27-5
分子类型	抗体

关联靶点（人）

PCSK9 Tclin 前蛋白转化酶枯草溶菌素/kexin 9 型(Proprotein convertase subtilisin/kexin type 9) (0 活性数据)

点击查看靶蛋白信息： PCSK9

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

PCSK9 Tclin Subtilisin/kexin type 9 (362 活性数据)

点击查看靶蛋白信息： PCSK9

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

SEC: Evolocumab (anti- PCSK9) (Ab169287)

Evolocumab (anti- PCSK9) (Ab169287) - SEC
The purity of Evolocumab (anti- PCSK9) (Ab169287) is more than 95% verified by HPLC.

ELISA: Evolocumab (anti-PCSK9) (Ab169287)

Evolocumab (anti-PCSK9) (Ab169287) - ELISA
Immobilized hu-PCSK9-chis at 2 μg/mL can bind Evolocumab (anti-PCSK9) (Ab169287) with the EC₅₀ of 14.03 ng/mL.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到4个结果

批号(Lot Number)	证书类型	货号
ZJ23F1001266	分析证书	Ab169287
ZJ23F1001265	分析证书	Ab169287
ZJ24F0911491	分析证书	Ab169287
ZJ24F0911490	分析证书	Ab169287

可替换产品

引用文献

1. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D et al.. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.. Nat Genet, 34 (2): (154-6). [PMID:12730697]
2. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A. (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.. Arterioscler Thromb Vasc Biol, 24 (8): (1454-9). [PMID:15178557]
3. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. (2012) Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.. JAMA, 308 (23): (2497-506). [PMID:23128163]
4. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM et al.. (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.. N Engl J Med, 372 (16): (1500-9). [PMID:25773607]
5. Xu S, Luo S, Zhu Z, Xu J. (2019) Small molecules as inhibitors of PCSK9: Current status and future challenges.. Eur J Med Chem, 162 (212-233). [PMID:30448414]
6. Pettersen D, Fjellström O.. (2018) Small molecule modulators of PCSK9 - A literature and patent overview.. Bioorg Med Chem Lett, 28 (7): (1155-1160). [PMID:29519739] [10.1016/j.bmcl.2018.02.046]
7. Alleyne C,Amin RP,Bhatt B,Bianchi E,Blain JC,Boyer N,Branca D,Embrey MW,Ha SN,Jette K,Johns DG,Kerekes AD,Koeplinger KA,LaPlaca D,Li N,Murphy B,Orth P,Ricardo A,Salowe S,Seyb K,Shahripour A,Stringer JR,Sun Y,Tracy R,Wu C,Xiong Y,Youm H,Zokian HJ,Tucker TJ. (2020) Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.. J Med Chem, 63 (22): (13796-13824). [PMID:33170686] [10.1021/acs.jmedchem.0c01084]
8. Seidah, Nabil G NG and 8 more authors.. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.. Proceedings of the National Academy of Sciences of the United States of America, (4): [PMID:12552133]
9. Naureckiene, Saule S and 13 more authors.. (2003) Functional characterization of Narc 1, a novel proteinase related to proteinase K.. Archives of biochemistry and biophysics, (1): [PMID:14622975]
10. Kotowski, Ingrid K IK and 6 more authors.. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.. American journal of human genetics, [PMID:16465619]
11. Benjannet, Suzanne S, Rhainds, David D, Hamelin, Josée J, Nassoury, Nasha N and Seidah, Nabil G NG.. (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.. The Journal of biological chemistry, (13): [PMID:16912035]
12. Nassoury, Nasha N and 9 more authors.. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.. Traffic (Copenhagen, Denmark), [PMID:17461796]
13. Piper, Derek E DE and 7 more authors.. (2007) The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.. Structure (London, England : 1993), [PMID:17502100]
14. Ding, Keyue K, McDonough, Samantha J SJ and Kullo, Iftikhar J IJ.. (2007) Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species.. PloS one, (31): [PMID:17971861]
15. Poirier, Steve S and 9 more authors.. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.. The Journal of biological chemistry, (25): [PMID:18039658]
16. Fan, Daping D and 6 more authors.. (2008) Self-association of human PCSK9 correlates with its LDLR-degrading activity.. Biochemistry, (12): [PMID:18197702]
17. and Lopez, Dayami D.. (2008) PCSK9: an enigmatic protease.. Biochimica et biophysica acta, [PMID:18280815]
18. Dewpura, Thilina T and 6 more authors.. (2008) PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans.. The FEBS journal, [PMID:18498363]
19. Lambert, Gilles G, Charlton, Francesca F, Rye, Kerry-Anne KA and Piper, Derek E DE.. (2009) Molecular basis of PCSK9 function.. Atherosclerosis, [PMID:18649882]
20. Jonas, Mary Cabell MC, Costantini, Claudio C and Puglielli, Luigi L.. (2008) PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.. EMBO reports, [PMID:18660751]
21. Mayer, Gaétan G, Poirier, Steve S and Seidah, Nabil G NG.. (2008) Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.. The Journal of biological chemistry, (14): [PMID:18799458]
22. Horton, Jay D JD, Cohen, Jonathan C JC and Hobbs, Helen H HH.. (2009) PCSK9: a convertase that coordinates LDL catabolism.. Journal of lipid research, [PMID:19020338]
23. Abifadel, Marianne M and 7 more authors.. (2009) Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.. Human mutation, [PMID:19191301]
24. Abifadel, Marianne M and 13 more authors.. (2009) The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.. Human mutation, [PMID:19319977]
25. Yamamoto, Taichi T, Lu, Christine C and Ryan, Robert O RO.. (2011) A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor.. The Journal of biological chemistry, (18): [PMID:21149300]
26. Du, Fen F and 5 more authors.. (2011) Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.. The Journal of biological chemistry, (16): [PMID:22027821]
27. Chen, Yanqun Y and 6 more authors.. (2011) Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation.. Biochemical and biophysical research communications, (25): [PMID:22074827]
28. Huijgen, Roeland R and 7 more authors.. (2012) Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.. Human mutation, [PMID:22095935]
29. Slimani, Afef A and 14 more authors.. (2012) Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.. Atherosclerosis, [PMID:22417841]
30. Sharotri, Vikas V, Collier, Daniel M DM, Olson, Diane R DR, Zhou, Ruifeng R and Snyder, Peter M PM.. (2012) Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9).. The Journal of biological chemistry, (1): [PMID:22493497]
31. Sun, Hua H and 5 more authors.. (2012) Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.. Arteriosclerosis, thrombosis, and vascular biology, [PMID:22580899]
32. Zhang, Yingnan Y and 12 more authors.. (2014) Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.. The Journal of biological chemistry, (10): [PMID:24225950]
33. Ly, Kévin K and 9 more authors.. (2014) Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.. The Journal of biological chemistry, (20): [PMID:24808179]
34. Tagliabracci, Vincent S VS and 14 more authors.. (2015) A Single Kinase Generates the Majority of the Secreted Phosphoproteome.. Cell, (18): [PMID:26091039]
35. Devito, Fiorella F and 7 more authors.. (2015) Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.. Pharmacological research, [PMID:26455563]
36. Kosmas, Constantine E and 6 more authors.. (2018) Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.. Diseases (Basel, Switzerland), (13): [PMID:30011788]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Evolocumab(anti-PCSK9), 9 型枯草蛋白酶/kexin 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器